Fate of PLA and PCL-Based Polymeric Nanocarriers in Cellular and Animal Models of Triple-Negative Breast Cancer

Biomacromolecules
Leopoldo SitiaPaolo Bigini

Abstract

An integrated platform to assess the interaction between nanocarriers and biological matrices has been developed by our group using poly methyl-methacrylate nanoparticles. In this study, we exploited this platform to evaluate the behavior of two biodegradable formulations, poly-ε-caprolactone (PCL3) and poly lactic-acid (PLA8), respectively, in cellular and animal models of triple-negative breast cancer (TNBC). Both NPs shared the main physicochemical parameters (size, shape, ζ-potential) and exclusively differentiated on the material on which they are composed. Our results showed that (1) PLA8 NPs, systemically injected in mice, underwent rapid degradation without penetration into tumors; (2) PLA8 NPs were not internalized in the human TNBC cell line (MDA-MB-231); (3) PCL3 NPs had a longer bioavailability, reached the tumor parenchyma, and efficiently penetrated in MDA-MB-231 cells. Our data highlight the relevance of the material selection to both improve bioavailability and target tropism, and make PCL3 NPs an interesting tool for the development of nanodrugs against TNBC.

References

Feb 13, 2001·Journal of Controlled Release : Official Journal of the Controlled Release Society·K S SoppimathW E Rudzinski
Dec 23, 2006·Biochemical and Biophysical Research Communications·Oshrat Harush-FrenkelYoram Altschuler
Jul 10, 2008·Molecular Pharmaceutics·Shyh-Dar Li, Leaf Huang
Aug 5, 2008·Molecular Pharmaceutics·Frank AlexisOmid C Farokhzad
Aug 14, 2008·Macromolecular Bioscience·Julia DausendVolker Mailänder
Sep 22, 2009·Methods in Molecular Biology·Alessandro EspositoAsparouh I Iliev
Jul 10, 2010·Nature Reviews. Drug Discovery·Robby A Petros, Joseph M DeSimone
Nov 12, 2010·Journal of Cancer Research and Clinical Oncology·Tim C de RuijterVivianne C Tjan-Heijnen
Jun 8, 2011·Current Drug Discovery Technologies·Xinyu RongYuanyuan Liu
Jul 29, 2011·Nanomedicine·Joao Paulo Mattos AlmeidaRebekah Drezek
Nov 1, 2011·Annual Review of Pharmacology and Toxicology·S M MoghimiT L Andresen
Mar 6, 2012·Chemical Society Reviews·Nazila KamalyOmid C Farokhzad
Jun 6, 2012·Journal of Controlled Release : Official Journal of the Controlled Release Society·Qihang SunYouqing Shen
Jun 12, 2012·Nanomedicine : Nanotechnology, Biology, and Medicine·Michael L EtheridgeJeffrey McCullough
Jun 26, 2012·Advanced Drug Delivery Reviews·Simona Mura, Patrick Couvreur
Jul 24, 2012·Advanced Drug Delivery Reviews·Miroslaw JanowskiPiotr Walczak
Oct 26, 2012·Current Opinion in Allergy and Clinical Immunology·Emanuela Fabiola Craparo, Maria Luisa Bondì
Jan 11, 2013·Journal of the Royal Society, Interface·Tais A P F DollPeter Burkhard
Mar 6, 2013·Current Medicinal Chemistry·G TosiG M Severini
Apr 27, 2013·Biomacromolecules·Kimberly Ann V ZubrisMark W Grinstaff
May 22, 2013·Nanotechnology·Lidia CovaDavide Moscatelli
Jun 12, 2013·Current Medicinal Chemistry·C LicoL Santi
Aug 7, 2013·European Journal of Pharmaceutics and Biopharmaceutics : Official Journal of Arbeitsgemeinschaft Für Pharmazeutische Verfahrenstechnik E.V·C MattuZ Ramtoola
Aug 24, 2013·Nanomedicine : Nanotechnology, Biology, and Medicine·Xiaolong JingJianming Chen
Feb 12, 2014·Proceedings of the National Academy of Sciences of the United States of America·Julia VoigtV Prasad Shastri
Apr 1, 2014·Current Topics in Medicinal Chemistry·Khairunnisa Abdul GhaffarIstvan Toth
May 17, 2014·Nanomedicine : Nanotechnology, Biology, and Medicine·Seyed Moein Moghimi, Zahra Shadi Farhangrazi
Jul 2, 2014·Journal of Controlled Release : Official Journal of the Controlled Release Society·Basit YameenOmid C Farokhzad
Aug 6, 2014·International Journal of Nanomedicine·Ciprian TomuleasaIoana Berindan-Neagoe
Dec 10, 2014·Nanomedicine·Caroline Lonez, Jean-Marie Ruysschaert
Aug 8, 2015·Cancer Research·Charlene M DawidczykPeter C Searson

❮ Previous
Next ❯

Citations

May 31, 2017·Advanced Healthcare Materials·Pravin Bhattarai, Zhifei Dai
Feb 7, 2020·Biomaterials Science·Maura C BelangerRebecca R Pompano
Feb 6, 2017·Biomacromolecules·Caroline KerrCassandra L Fraser

❮ Previous
Next ❯

Related Concepts

Related Feeds

Breast Cancer Triple-N

Breast cancer cells have receptors for estrogen, progesterone, HER2 receptors (also called ERBB2). Triple-negative breast cancers do not have any of these receptors. Here are the latest discoveries pertaining to triple-negative breast cancers.